Avecho Biotechnology (AVE) Stock Price, News & Analysis

Company Overview

Avecho Biotechnology Limited, a biotechnology company, engages in the development and commercialization of human and animal health related products using its proprietary drug delivery system and Tocopherol Phosphate Mixture in Australia. The company operates through Production and Human Health segments. It also produces and sells TPM and Vital ET products for use in drug delivery and cosmetic formulations. In addition, the company's human health portfolio covers delivery of pharmaceutical products through gels, injectables, and patches. Further, it develops feed additive products to enhance feed efficiency and the health of livestock animals. The company has a collaboration with Lambert Initiative at the University of Sydney for treatment of osteoarthritis. The company was incorporated in 1992 and is based in Clayton, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: A$15.85 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: ASX:AVE
• CIK: N/A
• Web: avecho.com.au
• Phone: 61 3 9002 5000
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -A$3.48 million
• Net Margins: -1,026.91%
• Pretax Margin: N/A
• Return on Equity: -65.78%
• Return on Assets: -44.33%

Debt

• Debt-to-Equity Ratio: 3.26
• Current Ratio: 3.54
• Quick Ratio: 5.97

Sales & Book Value

• Annual Sales: A$1.13 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: A$0.00 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 3,170,000,000
• Free Float: N/A
• Market Cap: A$15.85 million
• Optionable: Not Optionable
• Beta: 2.07